High-dose O
growth O
hormone O
does O
not O
affect O
proinflammatory B-protein
cytokine I-protein
( O
tumor B-protein
necrosis I-protein
factor-alpha I-protein
, O
interleukin-6 B-protein
, O
and O
interferon-gamma B-protein
) O
release O
from O
activated O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
or O
after O
minimal O
to O
moderate O
surgical O
stress O
. O

High-dose O
GH O
therapy O
, O
with O
GH O
doses O
10-20 O
times O
the O
normal O
replacement O
dose O
for O
GH-deficient O
adults O
, O
has O
been O
used O
as O
an O
anti-catabolic O
agent O
in O
a O
number O
of O
different O
patient O
groups O
. O

A O
recent O
study O
, O
however O
, O
has O
shown O
an O
increase O
in O
mortality O
in O
critically O
ill O
patients O
treated O
with O
high-dose O
GH O
. O

The O
increased O
mortality O
was O
associated O
with O
multiorgan O
failure O
, O
septic O
shock O
, O
and O
uncontrolled O
infection O
, O
suggesting O
that O
GH O
may O
have O
altered O
the O
immune O
response O
. O

The O
GH B-protein
receptor I-protein
and O
GH O
are O
both O
expressed O
in O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
( I-cell_type
PBMCs I-cell_type
) I-cell_type
; O
thus O
, O
GH O
could O
act O
as O
either O
an O
endocrine O
or O
an O
autocrine O
modulator O
of O
the O
immune O
response O
. O

We O
have O
examined O
the O
hypothesis O
that O
high-dose O
GH O
therapy O
may O
induce O
proinflammatory B-protein
cytokines I-protein
, O
which O
are O
implicated O
in O
septic O
shock O
. O

To O
do O
this O
we O
measured O
cytokine O
production O
by O
PBMCs B-cell_type
incubated O
in O
conditions O
that O
simulated O
high-dose O
GH O
therapy O
, O
and O
we O
measured O
cytokine O
levels O
in O
patients O
undergoing O
laparoscopic O
cholecystectomy O
who O
were O
randomized O
to O
receive O
either O
high-dose O
GH O
therapy O
( O
13 O
IU/m2 O
x O
day O
) O
or O
placebo O
. O

To O
confirm O
the O
biological O
activity O
of O
GH O
in O
our O
cell O
culture O
system O
we O
used O
a O
Stat5 O
functional O
assay O
. O

In O
this O
assay O
GH O
induced O
a O
bell-shaped O
curve O
, O
with O
a O
maximal O
response O
at O
GH O
levels O
between O
100-1 O
, O
000 O
ng/mL O
. O

PBMCs B-cell_type
from O
healthy O
volunteers O
were O
incubated O
with O
GH O
in O
doses O
from O
1-1 O
, O
000 O
ng/mL O
for O
6-72 O
h O
under O
resting O
conditions O
and O
after O
activation O
with O
endotoxin O
and O
the O
mixed O
lymphocyte B-cell_type
reaction O
. O

Studies O
were O
repeated O
with O
PBMCs B-cell_type
from O
six O
individuals O
using O
a O
GH O
dose O
of O
100 O
ng/mL O
( O
the O
level O
of O
GH O
found O
after O
high-dose O
GH O
therapy O
) O
and O
an O
endotoxin O
dose O
that O
gave O
a O
submaximal O
response O
( O
0.01 O
ng/mL O
) O
. O

GH O
had O
no O
effect O
on O
cell O
proliferation O
or O
the O
production O
of O
tumor B-protein
necrosis I-protein
factor-alpha I-protein
( I-protein
TNFalpha I-protein
) I-protein
, O
interleukin-6 B-protein
( I-protein
IL-6 I-protein
) I-protein
, O
or O
interferon-gamma B-protein
( I-protein
IFNgamma I-protein
) I-protein
. O

In O
patients O
undergoing O
laparoscopic O
cholecystectomy O
there O
was O
a O
time-related O
effect O
of O
surgery O
on O
cytokine O
levels O
. O

There O
was O
a O
rise O
in O
IL-6 B-protein
and O
a O
fall O
in O
TNFalpha B-protein
at O
24 O
h O
after O
surgery O
; O
however O
, O
high-dose O
GH O
therapy O
had O
no O
effect O
on O
the O
cytokine O
response O
. O

We O
considered O
the O
possibility O
that O
endogenous O
GH O
production O
by O
PBMCs B-cell_type
could O
influence O
the O
cytokine O
response O
in O
activated O
PBMCs B-cell_type
; O
however O
, O
incubation O
of O
PBMCs B-cell_type
in O
the O
presence O
of O
the O
GH B-protein
receptor I-protein
antagonist O
, O
B2036 O
, O
had O
no O
effect O
on O
TNFalpha B-protein
, O
IL-6 B-protein
, O
or O
IFNgamma B-protein
production O
by O
PBMCs B-cell_type
in O
either O
the O
mixed O
lymphocyte B-cell_type
reaction O
or O
when O
activated O
by O
endotoxin O
. O

These O
results O
suggest O
that O
high-dose O
GH O
therapy O
does O
not O
alter O
the O
proinflammatory B-protein
cytokine I-protein
response O
to O
surgery O
or O
endotoxin O
. O

The O
results O
do O
not O
exclude O
an O
effect O
of O
GH O
on O
the O
immune O
response O
, O
but O
they O
suggest O
that O
the O
mortality O
seen O
in O
critically O
ill O
patients O
may O
be O
due O
to O
factors O
other O
than O
immune O
modulation O
. O

Interaction O
between O
interferon B-protein
consensus I-protein
sequence-binding I-protein
protein I-protein
and O
COP9/signalosome B-protein
subunit I-protein
CSN2 I-protein
( I-protein
Trip15 I-protein
) I-protein
. O

A O
possible O
link O
between O
interferon B-protein
regulatory I-protein
factor I-protein
signaling O
and O
the O
COP9/signalosome B-protein
. O

Interferon B-protein
consensus I-protein
sequence-binding I-protein
protein I-protein
( I-protein
ICSBP I-protein
) I-protein
is O
a O
member O
of O
the O
interferon B-protein
regulatory I-protein
factors I-protein
( I-protein
IRF I-protein
) I-protein
that O
has O
a O
pivotal O
role O
in O
mediating O
resistance O
to O
pathogenic O
infections O
in O
mice O
and O
in O
promoting O
the O
differentiation O
of O
myeloid B-cell_type
cells I-cell_type
. O

ICSBP B-protein
exerts O
some O
of O
its O
transcriptional O
activities O
via O
association O
with O
other O
factors O
that O
enable O
its O
binding O
to O
a O
variety O
of O
promoters B-DNA
containing O
DNA B-DNA
composite I-DNA
elements I-DNA
. O

These O
interactions O
are O
mediated O
through O
a O
specific O
COOH-terminal B-protein
domain I-protein
termed O
IAD B-protein
( I-protein
IRF I-protein
association I-protein
domain I-protein
) I-protein
. O

To O
gain O
a O
broader O
insight O
of O
the O
capacity O
of O
ICSBP B-protein
to O
interact O
with O
other O
factors O
, O
yeast O
two-hybrid O
screens O
were O
performed O
using O
ICSBP-IAD B-protein
as O
a O
bait O
against O
a O
B-cell O
cDNA O
library O
. O

Trip15 B-protein
was O
identified O
as O
a O
specific O
interacting O
factor O
with O
ICSBP B-protein
in O
yeast B-cell_type
cells I-cell_type
, O
which O
was O
also O
confirmed O
by O
in O
vitro O
glutathione O
S-transferase O
pull-down O
assays O
and O
by O
coimmunoprecipitation O
studies O
in O
COS7 B-cell_line
cells I-cell_line
. O

Trip15 B-protein
was O
recently O
identified O
as O
a O
component O
of O
the O
COP9/signalosome B-protein
( I-protein
CSN I-protein
) I-protein
complex I-protein
composed O
of O
eight O
evolutionary O
conserved O
subunits O
and O
thus O
termed O
CSN2 B-protein
. O

This O
complex O
has O
a O
role O
in O
cell-signaling O
processes O
, O
which O
is O
manifested O
by O
its O
associated O
novel O
kinase O
activity O
and O
by O
the O
involvement O
of O
its O
subunits O
in O
regulating O
multiple O
cell-signaling O
pathways O
and O
cell-cycle O
progression O
. O

We O
show O
that O
in O
vitro O
association O
of O
ICSBP B-protein
with O
the O
CSN B-protein
leads O
to O
phosphorylation O
of O
ICSBP B-protein
at O
a O
unique O
serine O
residue O
within O
its O
IAD O
. O

The O
phosphorylated O
residue O
is O
essential O
for O
efficient O
association O
with O
IRF-1 B-protein
and O
thus O
for O
the O
repressor O
activity O
of O
ICSBP B-protein
exerted O
on O
IRF-1 B-protein
. O

This O
suggests O
that O
the O
CSN B-protein
has O
a O
role O
in O
integrating O
incoming O
signals O
that O
affect O
the O
transcriptional O
activity O
of O
ICSBP B-protein
. O

Intrathymic O
T O
cell O
development O
and O
selection O
proceeds O
normally O
in O
the O
absence O
of O
glucocorticoid O
receptor O
signaling O
. O

Glucocorticoids O
are O
believed O
to O
play O
a O
role O
in O
T B-cell_type
cell I-cell_type
development O
and O
selection O
, O
although O
their O
precise O
function O
is O
controversial O
. O

Glucocorticoid B-protein
receptor I-protein
( I-protein
GR I-protein
) I-protein
-deficient O
mice O
were O
used O
to O
directly O
investigate O
this O
problem O
. O

GR-deficient B-cell_type
thymocytes I-cell_type
were O
resistant O
to O
dexamethasone-mediated O
apoptosis O
, O
confirming O
the O
absence O
of O
glucocorticoid O
responsiveness O
. O

An O
absence O
of O
GR O
signaling O
had O
no O
impact O
on O
thymocyte B-cell_type
development O
either O
in O
vivo O
or O
in O
vitro O
. O

T B-cell_type
cell I-cell_type
differentiation O
, O
including O
positive O
selection O
, O
was O
normal O
as O
assessed O
by O
normal O
development O
of O
CD4+CD8+ B-cell_type
, I-cell_type
alphabetaTCR+CD4+ I-cell_type
, I-cell_type
and I-cell_type
alphabetaTCR+CD8+ I-cell_type
thymocytes I-cell_type
. O

Negative O
selection O
, O
mediated O
by O
the O
superantigen O
staphylococcal O
enterotoxin O
B O
( O
SEB O
) O
, O
or O
anti-CD3/CD28 B-protein
, O
was O
also O
normal O
in O
the O
absence O
of O
GR O
signaling O
. O

In O
contrast O
to O
earlier O
reports O
, O
these O
data O
demonstrate O
that O
GR O
signaling O
is O
not O
essential O
for O
intrathymic O
T B-cell_type
cell I-cell_type
development O
or O
selection O
. O

Rapid O
polarization O
of O
Th2 B-cell_type
cells I-cell_type
during O
induction O
of O
antigen-specific B-protein
IgE I-protein
antibodies I-protein
in O
vitro O
. O

BACKGROUND O
: O
Type B-cell_type
2 I-cell_type
T-helper I-cell_type
cells I-cell_type
( I-cell_type
Th2 I-cell_type
) I-cell_type
are O
involved O
in O
the O
regulation O
of O
the O
humoral O
immune O
response O
against O
antigens O
and O
allergens O
and O
directly O
affect O
which O
isotype O
will O
be O
produced O
. O

The O
mechanism O
that O
regulates O
antigen-specific O
IgE B-protein
secretion O
and O
immune O
deviation O
is O
still O
not O
known O
. O

OBJECTIVES O
: O
To O
delineate O
mechanisms O
behind O
antigen-specific O
IgE O
secretion O
we O
have O
used O
in O
vitro O
immunization O
and O
focused O
on O
T-cell O
phenotype O
and O
the O
activation O
status O
of O
the O
transcription B-protein
factor I-protein
NFkappaB I-protein
. O

METHODS O
: O
Peripheral B-cell_type
blood I-cell_type
lymphocytes I-cell_type
( I-cell_type
PBMC I-cell_type
) I-cell_type
from O
seronegative O
donors O
were O
immunized O
in O
vitro O
with O
a O
peptide O
consisting O
of O
both O
a O
T-cell B-cell_type
and O
a O
B-cell B-cell_type
epitope O
. O

RESULTS O
: O
Antigen-specific O
IgE B-protein
antibodies I-protein
could O
be O
detected O
after O
a O
primary O
immunization O
, O
during O
which O
T-helper B-cell_type
cells I-cell_type
secreted O
type B-protein
2 I-protein
cytokines I-protein
. O

Specific O
IgE B-protein
was O
also O
detected O
in O
the O
secondary O
immunization O
, O
but O
due O
to O
a O
rapid O
polarization O
from O
Th2 O
to O
Th1 O
phenotype O
, O
exogenous O
IL-4 B-protein
was O
required O
for O
the O
specific O
IgE B-protein
secretion O
. O

Analysis O
of O
NFkappaB O
activation O
in O
B B-cell_type
and I-cell_type
T I-cell_type
cells I-cell_type
during O
primary O
and O
secondary O
immunization O
showed O
that O
NFkappaB B-protein
could O
be O
detected O
in O
both O
B B-cell_type
and I-cell_type
T I-cell_type
cells I-cell_type
during O
primary O
immunization O
, O
but O
was O
dependent O
on O
exogenous O
IL-4 B-protein
in O
the O
secondary O
immunization O
. O

CONCLUSION O
: O
This O
is O
the O
first O
evidence O
of O
antigen-specific O
IgE B-protein
induction O
in O
vitro O
using O
naive B-cell_type
B I-cell_type
cells I-cell_type
, O
demonstrating O
the O
involvement O
of O
T-helper O
cell O
phenotype O
and O
NFkappaB B-protein
and O
demonstrates O
the O
usefulness O
of O
in O
vitro O
cultures O
to O
study O
the O
effect O
of O
antigens O
on O
human B-cell_type
immunocytes I-cell_type
. O

Pulmonary O
function O
changes O
and O
increased O
Th-2 B-protein
cytokine I-protein
expression O
and O
nuclear B-protein
factor I-protein
kB I-protein
activation O
in O
the O
lung O
after O
sensitization O
and O
allergen O
challenge O
in O
brown O
Norway O
rats O
. O

BACKGROUND O
: O
Our O
purpose O
was O
to O
evaluate O
the O
expression O
of O
Th-1 B-RNA
and I-RNA
Th-2 I-RNA
related I-RNA
cytokine I-RNA
mRNA I-RNA
and O
nuclear B-protein
factor I-protein
( I-protein
NF I-protein
) I-protein
kB I-protein
in O
the O
lung O
tissue O
of O
ovalbumin O
( O
OA O
) O
sensitized O
brown O
Norway O
rats O
( O
BNR O
) O
. O

We O
also O
evaluated O
the O
correlation O
between O
bronchial O
hyperreactivity O
( O
BHR O
) O
and O
eosinophils B-cell_type
with O
cytokine O
mRNA O
expression O
. O

METHODS O
: O
Eight O
BNR O
( O
weight O
range O
250-350 O
g O
) O
were O
sensitized O
by O
inhaled O
OA O
( O
group O
I O
) O
with O
a O
1-week O
interval O
between O
and O
then O
provoked O
with O
OA O
1 O
week O
later O
. O

Pulmonary O
function O
tests O
( O
PFT O
) O
were O
performed O
at O
baseline O
and O
24 O
h O
after O
acetylcholine O
challenge O
. O

Eight O
weight-matched O
normal O
BNR O
served O
as O
controls O
( O
group O
II O
) O
. O

All O
animals O
were O
anesthetized O
, O
paralyzed O
with O
gallamine O
, O
and O
ventilated O
via O
tracheostomy O
. O

They O
were O
given O
varying O
doses O
of O
acetylcholine O
( O
25 O
, O
50 O
, O
75 O
, O
100 O
microg/kg O
) O
injected O
through O
a O
jugular O
venous O
catheter O
. O

Five O
seconds O
after O
acetylcholine O
injections O
, O
PFTs O
were O
performed O
, O
including O
a O
maximal O
forced O
expiratory O
maneuver O
( O
MFEM O
) O
, O
airway O
opening O
pressure O
( O
P O
( O
ao O
) O
) O
at O
tidal O
breathing O
and O
total O
dynamic O
lung O
compliance O
( O
C O
( O
dyn O
) O
) O
. O

Bronchoalveolar O
lavage O
( O
BAL O
) O
was O
then O
performed O
with O
20 O
ml O
normal O
saline O
divided O
into O
two O
doses O
. O

Thereafter O
, O
the O
lungs O
were O
removed O
and O
examined O
histologically O
. O

Total O
RNA O
was O
extracted O
from O
lung O
tissue O
samples O
and O
reverse-transcriptase O
polymerase O
chain O
reaction O
was O
performed O
using O
primers O
for O
mRNA O
of O
IL-4 B-RNA
, O
IL-5 B-RNA
, O
IL-10 B-RNA
, O
interferon-gamma B-RNA
( I-RNA
IFNr I-RNA
) I-RNA
and O
beta-actine B-RNA
. O

RESULTS O
: O
Group O
I O
OA O
treated O
rats O
had O
typical O
airway O
obstruction O
on O
PFTs O
and O
airway O
inflammation O
on O
histological O
examination O
. O

Ratios O
of O
IL-4 B-RNA
, O
IL-5 B-RNA
, O
IL-10 B-RNA
and O
inducible O
nitric B-RNA
oxide I-RNA
synthase I-RNA
( I-RNA
iNOS I-RNA
) I-RNA
mRNA I-RNA
levels O
to O
beta-actine B-RNA
as O
measured O
by O
densitometry O
were O
significantly O
lower O
in O
controls O
than O
in O
OA-sensitized O
rats O
. O

The O
IFNr O
mRNA O
to O
beta-actin O
ratio O
was O
significantly O
reduced O
in O
OA-sensitized O
rats O
. O

Group O
I O
demonstrated O
a O
band O
shift O
when O
compared O
with O
group O
II O
in O
electromobility O
shift O
assay O
( O
EMSA O
) O
for O
NF-kB B-protein
indicating O
increased O
activation O
of O
this O
transcription B-protein
factor I-protein
. O

CONCLUSION O
: O
Th-2 B-RNA
related I-RNA
cytokine I-RNA
mRNA I-RNA
was O
increased O
but O
Th-1 B-RNA
related I-RNA
cytokine I-RNA
mRNA I-RNA
was O
decreased O
in O
OA-sensitized O
BNR O
. O

An O
increased O
level O
of O
Th-2 B-RNA
related I-RNA
cytokine I-RNA
mRNA I-RNA
correlated O
with O
decreased O
airflow O
and O
inflammatory O
changes O
. O

These O
results O
demonstrate O
the O
value O
of O
the O
BNR O
model O
for O
studying O
allergic O
asthma O
at O
the O
molecular O
level O
. O

3 O
, O
5-Bis O
( O
trifluoromethyl O
) O
pyrazoles O
: O
a O
novel O
class O
of O
NFAT O
transcription O
factor O
regulator O
. O

A O
series O
of O
bis O
( O
trifluoromethyl O
) O
pyrazoles O
( O
BTPs O
) O
has O
been O
found O
to O
be O
a O
novel O
inhibitor O
of O
cytokine O
production O
. O

Identified O
initially O
as O
inhibitors O
of O
IL-2 B-protein
synthesis O
, O
the O
BTPs O
have O
been O
optimized O
in O
this O
regard O
and O
even O
inhibit O
IL-2 B-protein
production O
with O
a O
10-fold O
enhancement O
over O
cyclosporine O
in O
an O
ex O
vivo O
assay O
. O

Additionally O
, O
the O
BTPs O
show O
inhibition O
of O
IL-4 B-protein
, O
IL-5 B-protein
, O
IL-8 B-protein
, O
and O
eotaxin O
production O
. O

Unlike O
the O
IL-2 B-protein
inhibitors O
, O
cyclosporine O
and O
FK506 O
, O
the O
BTPs O
do O
not O
directly O
inhibit O
the O
dephosphorylation O
of O
NFAT B-protein
by O
calcineurin B-protein
. O

A O
repression-derepression O
mechanism O
regulating O
the O
transcription O
of O
human O
immunodeficiency O
virus O
type O
1 O
in O
primary B-cell_type
T I-cell_type
cells I-cell_type
. O

BACKGROUND O
: O
Despite O
some O
controversy O
regarding O
the O
preferential O
infection O
and O
replication O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
, O
it O
appears O
that O
primary B-cell_type
T I-cell_type
lymphocytes I-cell_type
, O
in O
their O
quiescent O
state O
, O
are O
nonpermissive O
for O
viral O
expression O
and O
propagation O
. O

Massive O
activation O
of O
viral O
gene O
expression O
occurs O
only O
when O
the O
host O
lymphocyte B-cell_type
is O
activated O
. O

These O
observations O
prompted O
us O
to O
investigate O
the O
transcriptional O
regulation O
of O
HIV-1 O
in O
resting O
or O
activated O
T B-cell_type
cells I-cell_type
that O
were O
isolated O
from O
cord O
blood O
or O
adult O
peripheral O
blood O
. O

MATERIALS O
AND O
METHODS O
: O
To O
this O
end O
, O
we O
employed O
cellular O
purification O
and O
phenotyping O
techniques O
, O
in O
vitro O
protein-DNA O
binding O
studies O
, O
functional O
transactivation O
assays O
using O
proteins O
isolated O
from O
cord O
blood O
or O
adult O
peripheral O
blood O
T B-cell_type
lymphocytes I-cell_type
, O
and O
transfection O
experiments O
in O
primary B-cell_type
T I-cell_type
cells I-cell_type
. O

RESULTS O
: O
We O
showed O
that O
transcription O
from O
the O
HIV-1 O
long B-DNA
terminal I-DNA
repeat I-DNA
is O
repressed O
in O
resting B-cell_type
naive I-cell_type
T I-cell_type
lymphocytes I-cell_type
; O
whereas O
, O
mitogenically B-cell_type
stimulated I-cell_type
CD4+ I-cell_type
cells I-cell_type
form O
an O
activator O
that O
derepresses O
transcription O
. O

Negative O
and O
positive O
regulation O
act O
through O
a O
repressor-activator B-protein
target I-protein
sequence I-protein
( I-protein
RATS I-protein
) I-protein
, O
which O
shares O
homology O
with O
the O
interleukin-2 B-protein
( I-protein
IL-2 I-protein
) I-protein
purine-rich B-protein
response I-protein
element I-protein
, O
through O
the O
adjacent O
binding O
site O
of O
the O
nuclear B-protein
factor I-protein
of I-protein
activated I-protein
T I-protein
cells I-protein
( I-protein
NFAT I-protein
) I-protein
, O
and O
weakly O
, O
through O
the O
KB O
region O
. O

CONCLUSIONS O
: O
This O
regulation O
exerted O
by O
cellular O
transcription O
factors O
can O
account O
for O
several O
important O
features O
of O
HIV-1 O
expression O
in O
primary B-cell_type
CD4+ I-cell_type
cells I-cell_type
. O

Tight O
repression O
in O
resting B-cell_type
naive I-cell_type
T I-cell_type
helper I-cell_type
cells I-cell_type
may O
be O
a O
main O
cause O
of O
viral O
latency O
and O
transcriptional O
activation O
accounts O
for O
massive O
viral O
production O
in O
activated O
T B-cell_type
lymphocytes I-cell_type
. O

Involvement O
of O
lipopolysaccharide B-protein
binding I-protein
protein I-protein
, I-protein
CD14 I-protein
, O
and O
Toll-like B-protein
receptors I-protein
in O
the O
initiation O
of O
innate O
immune O
responses O
by O
Treponema O
glycolipids O
. O

Culture O
supernatants O
from O
Treponema O
maltophilum O
associated O
with O
periodontitis O
in O
humans O
and O
Treponema O
brennaborense O
found O
in O
a O
bovine O
cattle O
disease O
accompanied O
with O
cachexia O
caused O
a O
dose-dependent O
TNF-alpha O
synthesis O
in O
human B-cell_type
monocytes I-cell_type
increasing O
with O
culture O
time O
. O

This O
activity O
could O
be O
reduced O
significantly O
by O
blocking O
the O
CD14 B-protein
-part O
of O
the O
LPS B-protein
receptor I-protein
using O
the O
My B-protein
4 I-protein
mAb I-protein
and O
by O
polymyxin B-protein
B I-protein
. O

In O
the O
murine B-cell_line
macrophage I-cell_line
cell I-cell_line
line I-cell_line
RAW I-cell_line
264.7 I-cell_line
, O
Treponema O
culture O
supernatants O
induced O
TNF-alpha O
secretion O
in O
a O
LPS B-protein
binding I-protein
protein I-protein
( I-protein
LBP I-protein
) I-protein
-dependent O
fashion O
. O

To O
enrich O
for O
active O
compounds O
, O
supernatants O
were O
extracted O
with O
butanol O
, O
while O
whole O
cells O
were O
extracted O
using O
a O
phenol/water O
method O
resulting O
in O
recovery O
of O
material O
exhibiting O
a O
similar O
activity O
profile O
. O

An O
LPS-LBP O
binding O
competition O
assay O
revealed O
an O
interaction O
of O
the O
treponeme O
phenol/water O
extracts O
with O
LBP B-protein
, O
while O
precipitation O
studies O
implied O
an O
affinity O
to O
polymyxin B-protein
B I-protein
and O
endotoxin B-protein
neutralizing I-protein
protein I-protein
. O

Macrophages B-cell_type
obtained O
from O
C3H/HeJ O
mice O
carrying O
a O
Toll-like B-protein
receptor I-protein
( I-protein
TLR I-protein
) I-protein
-4 I-protein
mutation O
were O
stimulated O
with O
treponeme O
extracts O
for O
NO O
release O
to O
assess O
the O
role O
of O
TLRs B-protein
in O
cell O
activation O
. O

Furthermore O
, O
NF-kappaB O
translocation O
in O
TLR-2-negative B-cell_type
Chinese I-cell_type
hamster I-cell_type
ovary I-cell_type
( I-cell_type
CHO I-cell_type
) I-cell_type
cells I-cell_type
was O
studied O
. O

We O
found O
that O
phenol/water-extracts O
of O
the O
two O
strains O
use O
TLRs B-protein
differently O
with O
T. B-cell_type
brennaborense-stimulating I-cell_type
cells I-cell_type
in O
a O
TLR-4-dependent O
fashion O
, O
while O
T. O
maltophilum-mediated O
activation O
apparently O
involved O
TLR-2 B-protein
. O

These O
results O
indicate O
the O
presence O
of O
a O
novel O
class O
of O
glycolipids O
in O
Treponema O
initiating O
inflammatory O
responses O
involving O
LBP B-protein
, O
CD14 B-protein
, O
and O
TLRs B-protein
. O

Integration O
of O
calcineurin B-protein
and O
MEF2 O
signals O
by O
the O
coactivator B-protein
p300 I-protein
during O
T-cell O
apoptosis O
. O

T-cell B-protein
antigen I-protein
receptor I-protein
( I-protein
TCR I-protein
) I-protein
-induced O
thymocyte O
apoptosis O
is O
mediated O
by O
calcium-dependent O
signal O
transduction O
pathways O
leading O
to O
the O
transcriptional O
activation O
of O
members O
of O
the O
Nur77 B-protein
family I-protein
. O

The O
major O
calcium- B-DNA
and I-DNA
calcineurin-responsive I-DNA
elements I-DNA
in O
the O
Nur77 B-DNA
promoter I-DNA
are O
binding O
sites O
for O
myocyte B-protein
enhancer I-protein
factor-2 I-protein
( I-protein
MEF2 I-protein
) I-protein
. O

It O
has O
been O
shown O
that O
nuclear B-protein
factor I-protein
of I-protein
activated I-protein
T I-protein
cells I-protein
( I-protein
NFAT I-protein
) I-protein
interacts O
with O
MEF2D B-protein
and O
enhances O
its O
transcriptional O
activity O
, O
offering O
a O
plausible O
mechanism O
of O
activation O
of O
MEF2D B-protein
by O
calcineurin B-protein
. O

We O
report O
here O
that O
NFATp B-protein
synergizes O
with O
MEF2D B-protein
to O
recruit O
the O
coactivator B-protein
p300 I-protein
for O
the O
transcription O
of O
Nur77 O
. O

Surprisingly O
, O
the O
enhancement O
of O
transcriptional O
activity O
of O
MEF2D B-protein
by O
NFATp B-protein
does O
not O
require O
its O
DNA-binding O
activity O
, O
suggesting O
that O
NFATp B-protein
acts O
as O
a O
coactivator O
for O
MEF2D B-protein
. O

Transient O
co-expression O
of O
p300 B-protein
, O
MEF2D B-protein
, O
NFATp B-protein
and O
constitutively O
active O
calcineurin B-protein
is O
sufficient O
to O
recapitulate O
TCR O
signaling O
for O
the O
selective O
induction O
of O
the O
endogenous O
Nur77 B-DNA
gene I-DNA
. O

These O
results O
implicate O
NFAT B-protein
as O
an O
important O
mediator O
of O
T-cell O
apoptosis O
and O
suggest O
that O
NFAT B-protein
is O
capable O
of O
integrating O
the O
calcineurin O
signaling O
pathway O
and O
other O
pathways O
through O
direct O
protein-protein O
interaction O
with O
other O
transcription B-protein
factors I-protein
. O

Induction O
or O
suppression O
of O
a O
B O
cell-specific O
response O
to O
self O
antigen O
in O
vivo O
is O
dependent O
upon O
dendritic B-cell_type
cell I-cell_type
activation O
via O
the O
TNF-alpha O
receptor O
at O
the O
time O
of O
antigen O
uptake O
. O

In O
this O
study O
we O
show O
that O
the O
retinal B-protein
autoantigen I-protein
, I-protein
S-antigen I-protein
, O
contains O
a O
functional O
TNF-alpha B-protein
homologous I-protein
domain I-protein
which O
stimulates O
maturation O
and O
differentiation O
of O
cultured B-cell_type
dendritic I-cell_type
cells I-cell_type
( I-cell_type
DC I-cell_type
) I-cell_type
or O
tissue B-cell_type
DC I-cell_type
via O
the O
p55 B-protein
TNF-alpha I-protein
receptor I-protein
. O

Tissue B-cell_type
DC I-cell_type
became O
more O
dendritiform O
in O
shape O
, O
and O
migrated O
into O
culture O
supernatant O
. O

S-antigen B-protein
also O
stimulated O
accumulation O
of O
cell B-protein
surface I-protein
MHC I-protein
class I-protein
II I-protein
antigen I-protein
with O
a O
corresponding O
loss O
of O
acidic O
intracellular O
vesicles O
, O
and O
induced O
IL-1beta B-RNA
and I-RNA
IL-12 I-RNA
mRNA I-RNA
expression O
in O
cultured B-cell_type
bone I-cell_type
marrow-derived I-cell_type
DC I-cell_type
. O

In O
addition O
, O
cultured O
splenic B-cell_type
DC I-cell_type
primed O
immune O
responses O
to O
S-antigen B-protein
in O
vivo O
in O
the O
absence O
of O
other O
, O
exogenous O
cytokine B-protein
sources O
. O

DC B-cell_type
pulsed O
with O
either O
retinal B-protein
S-antigen I-protein
or O
another O
retinal B-protein
autoantigen I-protein
, O
interphotoreceptor B-protein
retinoid I-protein
binding I-protein
protein I-protein
( I-protein
IRBP I-protein
) I-protein
, O
were O
able O
to O
stimulate O
naive O
T O
cell O
proliferation O
in O
vitro O
, O
but O
only O
S-antigen B-protein
-pulsed O
DC B-cell_type
were O
able O
to O
induce O
an O
immune O
response O
in O
vivo O
and O
initiate O
antibody O
class O
switching O
. O

In O
contrast O
, O
IRBP B-protein
-pulsed O
DC B-cell_type
had O
no O
detectable O
in O
vivo O
priming O
effect O
and O
IgG O
antibody O
levels O
remained O
suppressed O
even O
after O
immunization O
with O
IRBP B-protein
in O
complete O
Freund O
's O
adjuvant O
. O

These O
results O
indicate O
that O
DC B-cell_type
from O
the O
same O
precursor O
population O
can O
either O
induce O
or O
suppress O
a O
B O
cell-specific O
response O
to O
self O
antigen O
in O
vivo O
, O
the O
outcome O
being O
dependent O
upon O
DC B-cell_type
activation O
at O
the O
time O
of O
antigen O
uptake O

